KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) EPS (Basic) (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of EPS (Basic) data on record, last reported at -$0.27 in Q4 2025.

  • For Q4 2025, EPS (Basic) fell 50.0% year-over-year to -$0.27; the TTM value through Dec 2025 reached -$0.78, down 52.94%, while the annual FY2025 figure was -$0.78, 52.94% down from the prior year.
  • EPS (Basic) reached -$0.27 in Q4 2025 per AQST's latest filing, down from -$0.14 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.15 in Q1 2023 and bottomed at -$0.73 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.22, with a median of -$0.2 recorded in 2022.
  • Peak YoY movement for EPS (Basic): plummeted 371.43% in 2021, then surged 146.88% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.73 in 2021, then skyrocketed by 69.86% to -$0.22 in 2022, then skyrocketed by 36.36% to -$0.14 in 2023, then decreased by 28.57% to -$0.18 in 2024, then plummeted by 50.0% to -$0.27 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.27 in Q4 2025, -$0.14 in Q3 2025, and -$0.13 in Q2 2025.